ESC 24: Hot Line & Late-breaking Science Video Collection

Published: 15 August 2024

  • Views:

    Views Icon 2985
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

What's hot at the ESC Congress 2024?

Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.

  • Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen
  • For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
  • Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.

Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.

More from this programme

Part 1

View From the Thoraxcenter: What's Hot at ESC 24?

About the episode

ESC Congress 2024 — Transcatheter aortic valve replacement shows superiority over surgical aortic valve replacement for women with severe aortic stenosis.

Host, Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Helene Eltchaninoff (University Hospital of Rouen, FR) to discuss key findings from the RHEIA trial (NCT04160130; Optimapharm).

This prospective, randomised study aims to compare the safety and efficacy of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in women with severe symptomatic aortic stenosis. 432 patients across 48 locations from Europe were randomised 1:1 to receive either procedure. The trial followed patients for 1 year to assess outcomes, with a focus on comparing the two treatments in this specific patient population.

Investigators found that in women all-comers with severe aortic stenosis, TAVI with the Edwards Sapien 3 or Sapien 3 Ultra was superior to surgery for the primary composite endpoint of death, stroke, or rehospitalisation at one year. This was primarily driven by a lower rate of rehospitalisations. TAVI was found to have a lower incidence of new onset AF at 30 days, quicker recovery and a shorter hospital stay, but higher rates of paravalvular aortic regurgitation and new permanent pacemaker implantation.

Recorded remotely from Rouen and Hamilton, 2024.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology. 

Faculty Biographies

Helene Eltchaninoff

View full profile
Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.